Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jaime Laurel Schneider has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Adaptive Rewiring of Nucleotide Metabolism in Therapeutic Resistance

    by Bengisu Dayanc, Ganfei Xu, Xiaoshu Zhou, Jinpeng Chen, Noah Mueller, Harsimran Kaur, Breanna Pham, Satoshi Yoda, Jaime L. Schneider

    Therapeutic resistance remains a major barrier to durable cancer control and is increasingly recognized as a dynamic process shaped not only by genetic evolution but also by metabolic adaptation. Nucleotide metabolism is uniquely positioned at this interface, supporting DNA and RNA synthesis while also regulating signaling, energy homeostasis, redox balance, genome maintenance, and cellular stress responses. In this Review, we examine emerging evidence that cancer cells in solid tumors adapt nucleotide metabolism in response to therapeutic pressure through coordinated remodeling of de novo biosynthesis, nucleotide salvage, metabolite transport, and pathway-specific feedback mechanisms. We discuss how cytotoxic chemotherapy, targeted therapies, immunotherapies, and radiation impose distinct but convergent pressures on nucleotide homeostasis and how restoration or redistribution of nucleotide pools can promote survival, DNA repair, persistent oncogenic signaling, and immune evasion. We further highlight the reciprocal relationship between oncogenic signaling and nucleotide metabolism, as well as the contribution of tumor suppressor loss and the tumor microenvironment to context-specific metabolic dependencies. Rather than functioning only as a biosynthetic requirement of proliferating cells, nucleotide metabolism emerges as a flexible stress-response network that can facilitate adaptation to cancer therapy. Defining the mechanisms that maintain nucleotide balance in resistant tumors may reveal therapeutically actionable dependencies and inform rational combination strategies designed to prevent or overcome treatment resistance.

  • Open Access

    Aging dictates tumor-specific genomic alterations across cancer types

    by Isabella N. Grabski, Jaime L. Schneider, Sara Hanahan, Arvind Ravi, Justin F. Gainor, Kevin M. Haigis, Rafael A. Irizarry, Marcia C. Haigis

    Cancer risk increases exponentially with age. As the world's population grows older, the absolute number of cancer diagnoses and cancer-related deaths continues to rise globally, despite declines in age-adjusted cancer mortality in many high-income countries. However, there is still little known about how molecular features of tumors differ according to patient age and how these genomic alterations may impact the treatment of patients of advanced age compared to younger patients who are diagnosed with malignancy. In this study, we survey the largest clinically- and genomically-annotated database available and identify age-associated mutations across distinct cancer types, defined as genes whose mutation rates in cross-sectional cancer populations differ by age. By interrogating paired clinical and genomic data from the AACR Project GENIE database across brain, breast, colorectum, lung, pancreas, and skin cancers, we identified somatic mutations in tumors with distinct age-dependent patterns. We also uncovered age-specific associations in the co-mutation patterns among these genes, demonstrating relationships among mutations that strengthen or weaken with age, as well as connections between age-specific mutation patterns and environmental covariates. Finally, in an exploratory analysis, we observed age-associated trends between PTPRT mutations in lung cancer and clinical response to immune checkpoint inhibitors, highlighting the possibility that certain genomic alterations may differentially associate with outcomes across patient age groups.

  • Open Access

    Projecting Individualized Probabilities of Lifetime Total Cancer Risk Across a Population

    by Neel M. Butala, Noor Al-Hammadi, Asiri Ediriwickrema, Jaime L. Schneider, Aaron Fullerton, Jeya Balasubramanian, Parichoy Pal Choudhury, Nilanjan Chatterjee

    PURPOSE: A substantial proportion of cancers are preventable through established risk factor modification and evidence-based screening strategies. However, emerging screening technologies have created new challenges for clinicians in identifying which individuals may benefit most and how to contextualize these approaches within existing prevention frameworks. METHODS: We projected individualized probabilities of 10-year and lifetime cancer risk across a population as well as potential improvement with healthy behaviors in the UK Biobank (UKB). RESULTS: A total of 118 distinct variables were included across 38 cancer-specific models. The distribution of lifetime cancer risk had a rightward skew and wide variation for both men and women. The median lifetime cancer risk was 29.5% for men (IQR, 8.4%) and 21.0% for women (IQR, 8.8%). If all modifiable risk factors were set to the ideal state, this decreased to 20.5% for men (IQR, 3.9%) and 16.5% for women (IQR, 4.9%). There was considerable overlap between age groups, with men age 50-59 years at the 90th percentile having greater risk (11.9%) compared with men age 60-70 years at the 25th percentile (11.8%), and women age 40-49 years at the 90th percentile having greater risk (7.4%) compared with women age 50-59 years at the 60th percentile (6.8%) and women age 60-70 years at the 20th percentile (7.3%). CONCLUSION: Lifetime cancer risk varies widely across the UKB cohort, but this risk decreases substantially with risk factor modification. There was considerable overlap in 10-year cancer risk between age groups, suggesting that discussion regarding future screening guidelines should account for more than age and sex as more evidence becomes available in the future.

  • Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer

    by Jaime L. Schneider, Alona Muzikansky, Elizabeth Krueger, Justin F. Gainor, Jessica J. Lin, Susan Symes, Alice T. Shaw, Ibiayi Dagogo-Jack


  • Open Access

    Mass spectrometry methods and mathematical PK/PD model for decision tree-guided covalent drug development

    by Amin Hossain, Rutali R. Brahme, Brandon C. Miller, Jakal Amin, Marcela de Barros, Jaime L. Schneider, Jared R. Auclair, Carla Mattos, Qingping Wang, Nathalie Y. R. Agar, et al.

    Covalent drug discovery efforts are growing rapidly but have major unaddressed limitations. These include high false positive rates during hit-to-lead identification; the inherent uncoupling of covalent drug concentration and effect [i.e., uncoupling of pharmacokinetics (PK) and pharmacodynamics (PD)]; and a lack of bioanalytical and modeling methods for determining PK and PD parameters. We present a covalent drug discovery workflow that addresses these limitations. Our bioanalytical methods are based upon a mass spectrometry (MS) assay that can measure the percentage of drug-target protein conjugation (% target engagement) in biological matrices. Further we develop an intact protein PK/PD model (iPK/PD) that outputs PK parameters (absorption and distribution) as well as PD parameters (mechanism of action, protein metabolic half-lives, dose, regimen, effect) based on time-dependent target engagement data. Notably, the iPK/PD model is applicable to any measurement (e.g., bottom-up MS and other drug binding studies) that yields % of target engaged. A Decision Tree is presented to guide researchers through the covalent drug development process. Our bioanalytical methods and the Decision Tree are applied to two approved drugs (ibrutinib and sotorasib); the most common plasma off-target, human serum albumin; three protein targets (KRAS, BTK, SOD1), and to a promising SOD1-targeting ALS drug candidates.


  • GUK1 activation is a metabolic liability in lung cancer

    by Jaime L. Schneider, Kiran Kurmi, Yutong Dai, Ishita Dhiman, Shakchhi Joshi, Brandon M. Gassaway, Christian W. Johnson, Nicole Jones, Zongyu Li, Christian P. Joschko, et al.


  • Open Access

    Fuel for thought: targeting metabolism in lung cancer

    by Jaime L. Schneider, SeongJun Han, Christopher S. Nabel

    For over a century, we have appreciated that the biochemical processes through which micro- and macronutrients are anabolized and catabolized—collectively referred to as “cellular metabolism”—are reprogrammed in malignancies. Cancer cells in lung tumors rewire pathways of nutrient acquisition and metabolism to meet the bioenergetic demands for unchecked proliferation. Advances in precision medicine have ushered in routine genotyping of patient lung tumors, enabling a deeper understanding of the contribution of altered metabolism to tumor biology and patient outcomes. This paradigm shift in thoracic oncology has spawned a new enthusiasm for dissecting oncogenotype-specific metabolic phenotypes and creates opportunity for selective targeting of essential tumor metabolic pathways. In this review, we discuss metabolic states across histologic and molecular subtypes of lung cancers and the additional changes in tumor metabolic pathways that occur during acquired therapeutic resistance. We summarize the clinical investigation of metabolism-specific therapies, addressing successes and limitations to guide the evaluation of these novel strategies in the clinic. Beyond changes in tumor metabolism, we also highlight how non-cellular autonomous processes merit particular consideration when manipulating metabolic processes systemically, such as efforts to disentangle how lung tumor cells influence immunometabolism. As the future of metabolic therapeutics hinges on use of models that faithfully recapitulate metabolic rewiring in lung cancer, we also discuss best practices for harmonizing workflows to capture patient specimens for translational metabolic analyses.


  • Open Access

    Advances and future directions in ROS1 fusion-positive lung cancer

    by Mary C Boulanger, Jaime L Schneider, Jessica J Lin

    ROS1 gene fusions are an established oncogenic driver comprising 1%-2% of non–small cell lung cancer (NSCLC). Successful targeting of ROS1 fusion oncoprotein with oral small-molecule tyrosine kinase inhibitors (TKIs) has revolutionized the treatment landscape of metastatic ROS1 fusion-positive (ROS1+) NSCLC and transformed outcomes for patients. The preferred Food and Drug Administration-approved first-line therapies include crizotinib, entrectinib, and repotrectinib, and currently, selection amongst these options requires consideration of the systemic and CNS efficacy, tolerability, and access to therapy. Of note, resistance to ROS1 TKIs invariably develops, limiting the clinical benefit of these agents and leading to disease relapse. Progress in understanding the molecular mechanisms of resistance has enabled the development of numerous next-generation ROS1 TKIs, which achieve broader coverage of ROS1 resistance mutations and superior CNS penetration than first-generation TKIs, as well as other therapeutic strategies to address TKI resistance. The approach to subsequent therapy depends on the pace and pattern of progressive disease on the initial ROS1 TKI and, if known, the mechanisms of TKI resistance. Herein, we describe a practical approach for the selection of initial and subsequent therapies for metastatic ROS1+ NSCLC based on these clinical considerations. Additionally, we explore the evolving evidence for the optimal treatment of earlier-stage, non–metastatic ROS1+ NSCLC, while, in parallel, highlighting future research directions with the goal of continuing to build on the tremendous progress in the management of ROS1+ NSCLC and ultimately improving the longevity and well-being of people living with this disease.


  • Open Access

    Lorlatinib and capmatinib in a ROS1-rearranged NSCLC with MET-driven resistance: tumor response and evolution

    by Jaime L. Schneider, Khvaramze Shaverdashvili, Mari Mino-Kenudson, Subba R. Digumarthy, Andrew Do, Audrey Liu, Justin F. Gainor, Jochen K. Lennerz, Timothy F. Burns, Jessica J. Lin

    Acquired drug resistance remains a major problem across oncogene-addicted cancers. Elucidation of mechanisms of resistance can inform rational treatment strategies for patients relapsing on targeted therapies while offering insights into tumor evolution. Here, we report acquired MET amplification as a resistance driver in a ROS1-rearranged lung adenocarcinoma after sequential treatment with ROS1 inhibitors. Subsequent combination therapy with lorlatinib plus capmatinib, a MET-selective inhibitor, induced intracranial and extracranial tumor response. At relapse, sequencing of the resistant tumor revealed a MET D1246N mutation and loss of MET amplification. We performed integrated molecular analyses of serial tumor and plasma samples, unveiling dynamic alterations in the ROS1 fusion driver and MET bypass axis at genomic and protein levels and the emergence of polyclonal resistance. This case illustrates the complexity of longitudinal tumor evolution with sequential targeted therapies, highlighting challenges embedded in the current precision oncology paradigm and the importance of developing approaches that prevent resistance.


  • Open Access

    Supplementary Table S2 from Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers

    by Aparna R. Parikh, Amikasra Mojtahed, Jaime L. Schneider, Katie Kanter, Emily E. Van Seventer, Isobel J. Fetter, Ashraf Thabet, Madeleine G. Fish, Bezaye Teshome, Kathryn Fosbenner, et al.